Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 1.00 |
| ▸ | ITGAV | P06756 | 20/20 | 1.00 |
| ▸ | ITGB6 | P18564 | 14/20 | 1.00 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.77 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.77 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.77 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6223680 | 1.00 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA2B | |
| SCHEMBL6380184 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA2B | |
| SCHEMBL6222060 | 0.93 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA2B | |
| SCHEMBL6226396 | 0.90 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA2B | |
| SCHEMBL6226399 | 0.90 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA2B | |
| SCHEMBL8325975 | 0.90 | ITGB3 (0.82) | ITGB3ITGAVITGB6ITGB1ITGA2B | |
| SCHEMBL6224801 | 0.90 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6224805 | 0.90 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6224539 | 0.87 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA2B | |
| SCHEMBL8325935 | 0.87 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572210-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | claimed |
| US-20050020505-A1 | R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | claimed |
| WO-2004060376-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPRATION (US) | 2004-07-22 | — | — | WO | claimed |
| EP-1572210-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | Pharmacia Corporation (US) | 2005-09-14 | — | — | EP | disclosed |
| US-20050020505-A1 | R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | disclosed |
| WO-2004060376-A1 | THE R-ISOMER OF BETA AMINO ACID COMPOUNDS AS INTEGRIN RECEPTOR ANTAGONISTS DERIVATIVES | PHARMACIA CORPRATION (US) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020505-A1 | R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives | ITGA5, ITGAL, ITGB5 | ITGB3 9/4885ITGAV 4/4885ITGB6 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.